DK2273996T3 - HUMAN CARDIOVASCULAR PROGENITOR CELLS - Google Patents
HUMAN CARDIOVASCULAR PROGENITOR CELLS Download PDFInfo
- Publication number
- DK2273996T3 DK2273996T3 DK09726362.8T DK09726362T DK2273996T3 DK 2273996 T3 DK2273996 T3 DK 2273996T3 DK 09726362 T DK09726362 T DK 09726362T DK 2273996 T3 DK2273996 T3 DK 2273996T3
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- human
- population
- progenitor cells
- dkk1
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims description 86
- 210000000130 stem cell Anatomy 0.000 title claims description 54
- 210000004027 cell Anatomy 0.000 claims description 180
- 210000002242 embryoid body Anatomy 0.000 claims description 70
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 50
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 45
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 42
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 42
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 41
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 33
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 33
- 238000012258 culturing Methods 0.000 claims description 30
- 210000002889 endothelial cell Anatomy 0.000 claims description 21
- 108010023082 activin A Proteins 0.000 claims description 18
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 15
- 108010059616 Activins Proteins 0.000 claims description 14
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 14
- 239000000488 activin Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000004017 serum-free culture medium Substances 0.000 claims description 11
- 238000000684 flow cytometry Methods 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 5
- 239000012679 serum free medium Substances 0.000 claims 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 38
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 38
- 230000000747 cardiac effect Effects 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 230000004069 differentiation Effects 0.000 description 22
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 210000003716 mesoderm Anatomy 0.000 description 17
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 102000013814 Wnt Human genes 0.000 description 12
- 108050003627 Wnt Proteins 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000009067 heart development Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010195 expression analysis Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 210000002464 muscle smooth vascular Anatomy 0.000 description 8
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 7
- 230000001464 adherent effect Effects 0.000 description 7
- 230000003511 endothelial effect Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000001671 embryonic stem cell Anatomy 0.000 description 6
- 230000003394 haemopoietic effect Effects 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 108010054624 red fluorescent protein Proteins 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000001900 endoderm Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 4
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 4
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010014480 T-box transcription factor 5 Proteins 0.000 description 4
- 102100024755 T-box transcription factor TBX5 Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002064 heart cell Anatomy 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000010825 Actinin Human genes 0.000 description 3
- 108010063503 Actinin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 102000044880 Wnt3A Human genes 0.000 description 3
- 108700013515 Wnt3A Proteins 0.000 description 3
- 102000006783 calponin Human genes 0.000 description 3
- 108010086826 calponin Proteins 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000001811 primitive streak Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000001045 Connexin 43 Human genes 0.000 description 2
- 108010069241 Connexin 43 Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 description 2
- 102100027875 Homeobox protein Nkx-2.5 Human genes 0.000 description 2
- 101001062347 Homo sapiens Hepatocyte nuclear factor 3-beta Proteins 0.000 description 2
- 101000632197 Homo sapiens Homeobox protein Nkx-2.5 Proteins 0.000 description 2
- 101000713606 Homo sapiens T-box transcription factor TBX20 Proteins 0.000 description 2
- 101000652324 Homo sapiens Transcription factor SOX-17 Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 2
- 102100037506 Paired box protein Pax-6 Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100036833 T-box transcription factor TBX20 Human genes 0.000 description 2
- 102100030243 Transcription factor SOX-17 Human genes 0.000 description 2
- 102000008790 VE-cadherin Human genes 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108010018828 cadherin 5 Proteins 0.000 description 2
- 102000028861 calmodulin binding Human genes 0.000 description 2
- 108091000084 calmodulin binding Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003981 ectoderm Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007045 gastrulation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 210000003566 hemangioblast Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001020 neural plate Anatomy 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 2
- 229950010357 tetrodotoxin Drugs 0.000 description 2
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 2
- 230000025366 tissue development Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 101150068520 wnt3a gene Proteins 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- -1 DKKI Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100540419 Danio rerio kdrl gene Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100021374 Hepatocyte nuclear factor 3-gamma Human genes 0.000 description 1
- 108010090007 Homeobox Protein Nkx-2.5 Proteins 0.000 description 1
- 102000012808 Homeobox Protein Nkx-2.5 Human genes 0.000 description 1
- 102100037099 Homeobox protein MOX-1 Human genes 0.000 description 1
- 101000818741 Homo sapiens Hepatocyte nuclear factor 3-gamma Proteins 0.000 description 1
- 101000955035 Homo sapiens Homeobox protein MOX-1 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 101150067565 Nfatc1 gene Proteins 0.000 description 1
- 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010051583 Ventricular Myosins Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4004908P | 2008-03-27 | 2008-03-27 | |
| PCT/US2009/038220 WO2009120762A2 (en) | 2008-03-27 | 2009-03-25 | Human cardiovascular progenitor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2273996T3 true DK2273996T3 (en) | 2017-03-27 |
Family
ID=41114664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09726362.8T DK2273996T3 (en) | 2008-03-27 | 2009-03-25 | HUMAN CARDIOVASCULAR PROGENITOR CELLS |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10077428B2 (enExample) |
| EP (1) | EP2273996B8 (enExample) |
| JP (1) | JP5801187B2 (enExample) |
| AU (1) | AU2009228354B2 (enExample) |
| CA (1) | CA2717962C (enExample) |
| DK (1) | DK2273996T3 (enExample) |
| IL (2) | IL208334A (enExample) |
| WO (1) | WO2009120762A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008211103B2 (en) * | 2007-01-30 | 2014-05-08 | University Of Georgia Research Foundation, Inc. | Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC) |
| CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| US20120301443A1 (en) * | 2009-12-29 | 2012-11-29 | Cornell University | Methods for developing endothelial cells from pluripotent cells and endothelial cells derived |
| US20120301445A1 (en) * | 2010-01-26 | 2012-11-29 | Universite Libre De Bruxelles | Tools for isolating and following cardiovascular progenitor cells |
| AU2010355614B2 (en) | 2010-06-13 | 2015-07-02 | Institute Of Biophysics, Chinese Academy Of Sciences | Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| US20140045265A1 (en) * | 2011-02-16 | 2014-02-13 | Salk Institute For Biological Studies | Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors |
| US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| GB201109882D0 (en) * | 2011-06-13 | 2011-07-27 | Cambridge Entpr Ltd | Population of smooth muscle cells of specific embryonic lineages |
| GB201121101D0 (en) * | 2011-12-08 | 2012-01-18 | Nhs Blood & Transplant | A method of preparing isolated cells and uses |
| EP2826855B1 (en) * | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| EP2891712A4 (en) * | 2012-07-23 | 2016-04-06 | Inst Biophysics Cn Acad Sci | METHOD FOR INDUCTING PLURIPOTENTAL STEM CELLS FOR DIFFERENTIATING VENTRICULAR IN MYOCYTES IN VITRO |
| JP5842289B2 (ja) * | 2013-05-31 | 2016-01-13 | ｉＨｅａｒｔ Ｊａｐａｎ株式会社 | 効率的な内皮細胞の誘導方法 |
| EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
| AU2014321101B2 (en) * | 2013-09-13 | 2020-12-03 | University Health Network | Methods and compositions for generating epicardium cells |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| GB201412554D0 (en) * | 2014-07-15 | 2014-08-27 | Cambridge Entpr Ltd | In vitro mesodermal differentiation |
| HK1248270A1 (zh) | 2015-02-17 | 2018-10-12 | 大学健康网路 | 制备和使用窦房结样起搏器心肌细胞和心室样心肌细胞的方法 |
| JP2018536438A (ja) | 2015-12-07 | 2018-12-13 | バイオタイム，インコーポレーテッド | 多様な多能性幹細胞から誘導された褐色脂肪細胞の再誘導のための方法 |
| US10612002B2 (en) | 2016-02-19 | 2020-04-07 | University Of Washington | Human pluripotent stem cell derived endocardial endothelium |
| WO2017147381A1 (en) * | 2016-02-25 | 2017-08-31 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Generation of expandable cardiovascular progenitor cells |
| JP2023524572A (ja) * | 2020-05-08 | 2023-06-12 | ユニバーシティー ヘルス ネットワーク | 心内膜細胞を作製および使用するための方法および組成物 |
| WO2023201361A1 (en) | 2022-04-15 | 2023-10-19 | Aspen Neuroscience, Inc. | Methods of classifying the differentiation state of cells and related compositions of differentiated cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
| US5919449A (en) * | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
| US20050021439A1 (en) * | 1999-04-09 | 2005-01-27 | Pinga Louis J. | Arcade casino and home investment system |
| IL159580A0 (en) * | 2001-07-12 | 2004-06-01 | Geron Corp | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| US20030082153A1 (en) | 2001-10-22 | 2003-05-01 | The Government Of The United States Of America | Stem cells that transform to beating cardiomyocytes |
| US20060003446A1 (en) | 2002-05-17 | 2006-01-05 | Gordon Keller | Mesoderm and definitive endoderm cell populations |
| WO2004094610A2 (en) * | 2003-04-21 | 2004-11-04 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US20050214938A1 (en) * | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
| US7452718B2 (en) * | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| KR20130099253A (ko) | 2005-06-22 | 2013-09-05 | 제론 코포레이션 | 영장류 다능성 줄기 세포의 심근세포 계통 세포로의 분화 |
| AU2006262098B2 (en) | 2005-06-23 | 2011-03-17 | Mount Sinai School Of Medicine Of New York University | Cardiomyocyte cell populations |
-
2009
- 2009-03-25 WO PCT/US2009/038220 patent/WO2009120762A2/en not_active Ceased
- 2009-03-25 US US12/410,782 patent/US10077428B2/en active Active
- 2009-03-25 JP JP2011502014A patent/JP5801187B2/ja active Active
- 2009-03-25 CA CA2717962A patent/CA2717962C/en active Active
- 2009-03-25 AU AU2009228354A patent/AU2009228354B2/en active Active
- 2009-03-25 DK DK09726362.8T patent/DK2273996T3/en active
- 2009-03-25 EP EP09726362.8A patent/EP2273996B8/en active Active
-
2010
- 2010-09-21 IL IL208334A patent/IL208334A/en active IP Right Grant
-
2015
- 2015-08-27 IL IL240870A patent/IL240870B/en active IP Right Grant
-
2018
- 2018-08-09 US US16/059,647 patent/US10947506B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2273996B8 (en) | 2017-04-26 |
| US10947506B2 (en) | 2021-03-16 |
| IL240870A0 (en) | 2015-10-29 |
| EP2273996A4 (en) | 2012-02-15 |
| CA2717962A1 (en) | 2009-10-01 |
| JP2011517563A (ja) | 2011-06-16 |
| US20180362931A1 (en) | 2018-12-20 |
| US20090269314A1 (en) | 2009-10-29 |
| EP2273996A2 (en) | 2011-01-19 |
| AU2009228354A1 (en) | 2009-10-01 |
| JP5801187B2 (ja) | 2015-10-28 |
| EP2273996B1 (en) | 2017-02-22 |
| CA2717962C (en) | 2019-05-14 |
| IL208334A0 (en) | 2010-12-30 |
| AU2009228354B2 (en) | 2015-01-22 |
| WO2009120762A3 (en) | 2009-12-30 |
| IL208334A (en) | 2015-09-24 |
| IL240870B (en) | 2019-08-29 |
| WO2009120762A2 (en) | 2009-10-01 |
| US10077428B2 (en) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2273996T3 (en) | HUMAN CARDIOVASCULAR PROGENITOR CELLS | |
| Cao et al. | Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions | |
| US8507275B2 (en) | Method of inducing differentiation of embryonic stem cells into hemangioblast | |
| CA2718032C (en) | Method for generating primate cardiovascular progenitor cells for clinical use from primate embryonic stem cells or embryonic-like state cells, and their applications | |
| US20210062153A1 (en) | Methods and compositions for generating epicardium cells | |
| CN103189502A (zh) | 基于sirpa表达富集源自多能干细胞的心肌祖细胞和心肌细胞的方法 | |
| US11607429B2 (en) | Derivation and self-renewal of ISI1+ cells and uses thereof | |
| US12492378B2 (en) | Stepwise method of producing various types of cells from pluripotent stem cells | |
| WO2017186273A1 (en) | Derivation and self-renewal of multipotent cells and uses thereof | |
| JP2024531682A (ja) | コミットされた心臓始原細胞の製造方法 | |
| WO2023017848A1 (ja) | 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法 | |
| JPWO2019189554A1 (ja) | 心筋細胞成熟促進剤 | |
| Braam et al. | SEVEN |